Plasma vitamin D and mortality in older men: A community-based prospective cohort study

American Journal of Clinical Nutrition

Volumn 92, Issue 4, 2010, Pages 841-848

  Michaëlsson, Karl ^a   Baron, John A ^b   Snellman, Greta ^a   Gedeborg, Rolf ^a   Byberg, Liisa ^a   Sundström, Johan ^a   Berglund, Lars ^a   Ärnlöv, Johan ^c,d   Hellman, Per ^a   Blomhoff, Rune ^e   Wolk, Alicja ^f   Garmo, Hans ^a,g   Holmberg, Lars ^a,g   Melhus, Håkan ^a  

^a UPPSALA UNIVERSITY   (Sweden)

^b DARTMOUTH MEDICAL SCHOOL   (United States)

^c UPPSALA UNIVERSITY   (Sweden)

^d University of Oslo ^*  (Sweden)

^e UNIVERSITY OF OSLO   (Norway)

^f KAROLINSKA INSTITUTE   (Sweden)

^g KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

25 HYDROXYERGOCALCIFEROL; 25 HYDROXYVITAMIN D; CALCIFEDIOL; 25-HYDROXYVITAMIN D; CALCIUM; CHOLESTEROL; DRUG DERIVATIVE; VITAMIN D;

AGED; ARTICLE; CANCER MORTALITY; COHORT ANALYSIS; COMMUNITY TRIAL; FOLLOW UP; GERIATRIC PATIENT; HEART DEATH; HUMAN; MALE; MORTALITY; RISK ASSESSMENT; VITAMIN BLOOD LEVEL; BLOOD; BLOOD PRESSURE; CARDIOVASCULAR DISEASE; ENERGY METABOLISM; LEISURE; LIFESTYLE; METABOLISM; PROPORTIONAL HAZARDS MODEL; SWEDEN;

AGED; AGED, 80 AND OVER; BLOOD PRESSURE; CALCIUM; CARDIOVASCULAR DISEASES; CHOLESTEROL; COHORT STUDIES; ENERGY METABOLISM; HUMANS; LEISURE ACTIVITIES; LIFE STYLE; MALE; MORTALITY; PROPORTIONAL HAZARDS MODELS; SWEDEN; VITAMIN D;

EID: 78049421068     PISSN: 00029165     EISSN: 19383207     Source Type: Journal    
DOI: 10.3945/ajcn.2010.29749     Document Type: Article

References (45)

1. Lee JH, O'Keefe JH, Bell D, Hensrud DD, Holick MF. Vitamin D deficiency an important, common, and easily treatable cardiovascular risk factor? J Am Coll Cardiol 2008;52:1949-56.
2. Holick MF. Vitamin D deficiency. N Engl J Med 2007;357:266-81.
3. Autier P, Gandini S. Vitamin D supplementation and total mortality: a meta-analysis of randomized controlled trials. Arch Intern Med 2007;167:1730-7.
4. Stolzenberg-Solomon RZ. Vitamin D and pancreatic cancer. Ann Epidemiol 2009;19:89-95.
5. Stolzenberg-Solomon RZ, Vieth R, Azad A, et al. A prospective nested case-control study of vitamin D status and pancreatic cancer risk in male smokers. Cancer Res 2006;66:10213-9.
6. Tuohimaa P, Tenkanen L, Ahonen M, et al. Both high and low levels of blood vitamin D are associated with a higher prostate cancer risk: a longitudinal, nested case-control study in the Nordic countries. Int J Cancer 2004;108:104-8.
7. Chen W, Dawsey SM, Qiao YL, et al. Prospective study of serum 25 (OH)-vitamin D concentration and risk of oesophageal and gastric cancers. Br J Cancer 2007;97:123-8.
8. Tuohimaa P. Vitamin D and aging. J Steroid Biochem Mol Biol 2009; 114:78-84.
9. Melamed ML, Michos ED, Post W, Astor B. 25-hydroxyvitamin D levels and the risk of mortality in the general population. Arch Intern Med 2008;168:1629-37.
10. Nagpal S, Na S, Rathnachalam R. Noncalcemic actions of vitamin D receptor ligands. Endocr Rev 2005;26:662-87.
11. Razzaque MS, Lanske B. Hypervitaminosis D and premature aging: lessons learned from Fgf23 and Klotho mutant mice. Trends Mol Med 2006;12:298-305.
12. Honjo Y, Sasaki S, Kobayashi Y, Misawa H, Nakamura H. 1,25-Dihydroxyvitamin D3 and its receptor inhibit the chenodeoxycholic acid-dependent transactivation by farnesoid X receptor. J Endocrinol 2006;188:635-43.
13. Albertson DG, Ylstra B, Segraves R, et al. Quantitative mapping of amplicon structure by array CGH identifies CYP24 as a candidate oncogene. Nat Genet 2000;25:144-6.
14. Zethelius B, Berglund L, Sundstrom J, et al. Use of multiple biomarkers to improve the prediction of death from cardiovascular causes. N Engl J Med 2008;358:2107-16.
15. Byberg L, Melhus H, Gedeborg R, et al. Total mortality after changes in leisure time physical activity in 50 year old men: 35 year follow-up of population based cohort. BMJ 2009;338:b688.
16. Ahn J, Peters U, Albanes D, et al. Serum vitamin D concentration and prostate cancer risk: a nested case-control study. J Natl Cancer Inst 2008;100:796-804.
17. Calltorp J, Adami HO, Astrom H, et al. Country profile: Sweden. Lancet 1996;347:587-94.
18. Smedman AE, Gustafsson IB, Berglund LG, Vessby BO. Pentadecanoic acid in serum as a marker for intake of milk fat: relations between intake of milk fat and metabolic risk factors. Am J Clin Nutr 1999;69: 22-9.
19. Makishima M, Lu TT, Xie W, et al. Vitamin D receptor as an intestinal bile acid sensor. Science 2002;296:1313-6.
20. Yang F, Huang X, Yi T, Yen Y, Moore DD, Huang W. Spontaneous development of liver tumors in the absence of the bile acid receptor farnesoid X receptor. Cancer Res 2007;67:863-7.
21. Maran RR, Thomas A, Roth M, et al. Farnesoid X receptor deficiency in mice leads to increased intestinal epithelial cell proliferation and tumor development. J Pharmacol Exp Ther 2009;328:469-77.
22. Schmidt DR, Mangelsdorf DJ. Nuclear receptors of the enteric tract: guarding the frontier. Nutr Rev 2008;66:S88-97.
23. Tunstall-Pedoe H, Kuulasmaa K, Amouyel P, Arveiler D, Rajakangas AM, Pajak A. Myocardial infarction and coronary deaths in the World Health Organization MONICA Project: registration procedures, event rates, and case-fatality rates in 38 populations from 21 countries in four continents. Circulation 1994;90:583-612.
24. Heinzl H, Kaider A. Gaining more flexibility in Cox proportional hazards regression models with cubic spline functions. Comput Methods Programs Biomed 1997;54:201-8.
25. Harrell FE Jr. General aspects of fitting regression models: regression modeling strategies. New York, NY: Springer Science+Business Media Inc, 2001:23.
26. Lips P. Vitamin D physiology. Prog Biophys Mol Biol 2006;92:4-8.
27. Contal C, O'Quigley J. An application of changepoint methods in studying the effect of age on survival in breast cancer. Comput Stat Data Anal 1999;30:253-70.
28. Mandrekar JN, Mandrekar SJ, Cha SS. Cutpoint determination methods in survival analysis using SAS. Proceedings of the 28th SAS Users Group International Conference (SUGI) 2003:261-28.
29. Sturmer T, Joshi M, Glynn RJ, Avorn J, Rothman KJ, Schneeweiss S. A review of the application of propensity score methods yielded increasing use, advantages in specific settings, but not substantially different estimates compared with conventional multivariable methods. J Clin Epidemiol 2006;59:437-47.
30. Fine JP, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc 1999;94:496-509.
31. Looker AC, Pfeiffer CM, Lacher DA, Schleicher RL, Picciano MF, Yetley EA. Serum 25-hydroxyvitamin D status of the US population: 1988-1994 compared with 2000-2004. Am J Clin Nutr 2008;88:1519-27.
32. Kuro-o M. Klotho as a regulator of oxidative stress and senescence. Biol Chem 2008;389:233-41.
33. Tsujikawa H, Kurotaki Y, Fujimori T, Fukuda K, Nabeshima Y. Klotho, a gene related to a syndrome resembling human premature aging, functions in a negative regulatory circuit of vitamin D endocrine system. Mol Endocrinol 2003;17:2393-403.
34. Makino T, Obara T, Ura H, et al. Effects of phenobarbital and secondary bile acids on liver, gallbladder, and pancreas carcinogenesis initiated by N-nitrosobis (2-hydroxypropyl)amine in hamsters. J Natl Cancer Inst 1986;76:967-75.
35. Kayed H, Bekasi S, Keleg S, et al. BGLAP is expressed in pancreatic cancer cells and increases their growth and invasion. Mol Cancer 2007; 6:83.
36. Ito S, Fujimori T, Furuya A, Satoh J, Nabeshima Y. Impaired negative feedback suppression of bile acid synthesis in mice lacking betaKlotho. J Clin Invest 2005;115:2202-8.
37. Tsugawa N, Suhara Y, Kamao M, Okano T. Determination of 25-hydroxyvitamin D in human plasma using high-performance liquid chromatography-tandem mass spectrometry. Anal Chem 2005;77:3001-7.
38. Snellman G, Melhus H, Gedeborg R, et al. Determining vitamin D status: a comparison between commercially available assays. PLoS ONE 2010;5:e11555.
39. Snellman G, Melhus H, Gedeborg R, et al. Seasonal genetic influence on serum 25-hydroxyvitamin D levels: a twin study. PLoS ONE 2009;4: e7747.
40. Steyerberg E. Coding of categorical and continuous predictors. In: Gail M, Tsiatis A, Krickeberg K, Wong W, Sarnet J , eds. Clinical prediction models. New York, NY: Springer, 2009:159-73.
41. Platz EA, Leitzmann MF, Hollis BW, Willett WC, Giovannucci E. Plasma 1,25-dihydroxy- and 25-hydroxyvitamin D and subsequent risk of prostate cancer. Cancer Causes Control 2004;15:255-65.
42. Dobnig H, Pilz S, Scharnagl H, et al. Independent association of low serum 25-hydroxyvitamin D and 1,25-dihydroxyvitamin d levels with all-cause and cardiovascular mortality. Arch InternMed 2008;168:1340-9.
43. Wang TJ, Pencina MJ, Booth SL, et al. Vitamin D deficiency and risk of cardiovascular disease. Circulation 2008;117:503-11.
44. Garland CF, Gorham ED, Mohr SB, Garland FC. Vitamin D for cancer prevention: global perspective. Ann Epidemiol 2009;19:468-83.
45. IARC. Vitamin D and cancer. IARC Working Group Reports Vol.5., 25 November 2008. Lyon, France: International Agency for Research on Cancer, 2008:2.